Qurient Co Ltd (115180)

Currency in KRW
16,560
-1,410(-7.85%)
Delayed Data·
115180 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16,55017,730
52 wk Range
9,52062,900
Key Statistics
Bid/Ask
16,550.00 / 16,560.00
Prev. Close
17,970
Open
17,660
Day's Range
16,550-17,730
52 wk Range
9,520-62,900
Volume
37.3K
Average Volume (3m)
144.96K
1-Year Change
58.0645%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
115180 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Qurient Co Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Earnings

Latest Release
May 15, 2026
EPS / Forecast
-204.14 / --
Revenue / Forecast
1.94B / --
EPS Revisions
Last 90 days

115180 Income Statement

Compare 115180 to Peers and Sector

Metrics to compare
115180
Peers
Sector
Relationship
P/E Ratio
−23.0x−11.4x−0.4x
PEG Ratio
1.95−0.490.00
Price/Book
26.5x2.4x2.6x
Price / LTM Sales
104.3x17.4x2.9x
Upside (Analyst Target)
-56.9%56.8%
Fair Value Upside
Unlock18.3%8.9%Unlock

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.14M2.80%20.23B
Other Institutional Investors
9.37M23.05%166.72B
Public Companies & Retail Investors
30.16M74.16%536.47B
Total
40.66M100.00%723.42B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
DongKoo Bio & Pharma Co., Ltd.11.22%4,563,87281,191,283
UAMCO-Keystone Corporate Restructuring Financial Stability PEF4.00%1,626,89828,942,515

People Also Watch

717,000
267260
-10.04%
14,530
950160
-8.67%
22,400
397030
-10.58%
1,170,000
003230
-4.10%
118,300
138040
-5.81%

FAQ

What Is the Qurient (115180) Stock Price Today?

The Qurient stock price today is 16,560 KRW.

What Stock Exchange Does Qurient Trade On?

Qurient is listed and trades on the KOSDAQ.

What Is the Stock Symbol for Qurient?

The stock symbol for Qurient is "115180."

What Is the Qurient Market Cap?

As of today, Qurient market cap is 730.74B KRW.

What Is Qurient's Earnings Per Share (TTM)?

The Qurient EPS (TTM) is -895.

From a Technical Analysis Perspective, Is 115180 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Qurient Stock Split?

Qurient has split 1 times.

What is the current trading status of Qurient (115180)?

As of Jul 28, 2026, Qurient (115180) is trading at a price of 16,560 KRW, with a previous close of 17,970 KRW. The stock has fluctuated within a day range of 16,550 KRW to 17,730 KRW, while its 52-week range spans from 9,520 KRW to 62,900 KRW.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.